Coya Therapeutics Raises $23 Million to Advance ALS Treatment Development
核心洞察
Coya Therapeutics completed a $23 million public offering to fund clinical development of its regulatory T cell-enhancing therapies for neurodegenerative disorders (搜索).
The company is currently conducting the ALSTARS Trial, a Phase 2 study evaluating COYA 302 for ALS (搜索) treatment using a dual immunomodulatory approach.
COYA 302 combines low-dose interleukin-2 and CTLA-4 Ig (搜索) to enhance anti-inflammatory Treg function and suppress monocyte-macrophage inflammation.
Coya Therapeutics, a clinical-stage biotechnology company developing regulatory T cell (Treg)-enhancing therapies, has successfully closed a $23.0 million underwritten public offering to advance its neurodegenerative disease treatment programs. The Houston-based company issued 4,181,818 shares of common stock at $5.50 per share, including 545,454 additional shares from the full exercise of the underwriter's option.
The offering attracted both existing investors and new biotechnology and healthcare-focused institutional investors, with Lucid Capital Markets (搜索) serving as sole book-running manager. Allele Capital Partners (搜索), through its executing broker-dealer Wilmington Capital Securities, acted as financial advisor to the company.
Advancing ALS Treatment Through Treg Biology
Coya's lead investigational candidate, COYA 302, represents a novel approach to treating amyotrophic lateral sclerosis (搜索) (ALS (搜索)) through dual immunomodulatory mechanisms. The proprietary biologic combination therapy comprises low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig (搜索), designed for subcutaneous administration to enhance the anti-inflammatory function of regulatory T cells (搜索) while suppressing inflammation produced by activated monocytes (搜索) and macrophages (搜索).
The company is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for ALS (搜索) treatment. The trial is registered under ClinicalTrials.gov Identifier NCT 07161999.
Targeting Treg Dysfunction in Neurodegeneration
Coya's therapeutic approach addresses a fundamental aspect of neurodegenerative disease pathology: dysfunctional regulatory T cells (搜索). According to the company, dysfunctional Tregs (搜索) underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases (搜索). This cellular dysfunction may lead to sustained inflammation and oxidative stress, resulting in lack of homeostasis of the immune system.
The company's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs (搜索). Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Financial Strategy and Development Plans
The gross proceeds from the public offering totaled approximately $23.0 million before deducting underwriting discounts, commissions, and estimated offering expenses. Coya intends to use the net proceeds for working capital and general corporate purposes, including funding its clinical development plan.
The common stock was offered pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission on August 19, 2025. COYA 302 remains an investigational product not yet approved by the FDA or any other regulatory agency.